AR046992A1 - Derivados de espiro-dihidrobenzofuranos - Google Patents

Derivados de espiro-dihidrobenzofuranos

Info

Publication number
AR046992A1
AR046992A1 ARP040104881A ARP040104881A AR046992A1 AR 046992 A1 AR046992 A1 AR 046992A1 AR P040104881 A ARP040104881 A AR P040104881A AR P040104881 A ARP040104881 A AR P040104881A AR 046992 A1 AR046992 A1 AR 046992A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
halogen
alkoxy
group
Prior art date
Application number
ARP040104881A
Other languages
English (en)
Inventor
Nafizal Hossain
Svetlana Ivanova
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046992A1 publication Critical patent/AR046992A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a derivados de espiro-dihidrobenzofuranos, procesos para su preparacion, composiciones farmacéuticas que los contienen y su uso en terapia. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde m es 0, 1, 2, 3 o 4, donde cada R1 representa independientemente halogeno, ciano, hidroxilo, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, alquilsulfonilo C1-6 o sulfonamido (-SO2NH2); X representa una union o -CH2- e Y representa una union o -CH2-, siempre y cuando X e Y no representen ambos simultáneamente una union o -CH2-; n es 0, 1 o 2; donde cada R2 representa independientemente halogeno, alquilo C1-6 o haloalquilo C1-6; q es 0 o 1; p es 0 o 2; R3 representa un grupo que se selecciona entre halogeno, NR6R7, carboxilo o alquilo C1-6 donde dicho grupo alquilo C1-6 opcionalmente está sustituido por uno o más de halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi o carbamoilo; R4 representa H, alquilo C1-6, haloalquilo C1-6 o halogeno; t es 0, 1 o 2, siempre y cuando p y t no sean ambos 0; R5 representa un sistema de anillo saturado o insaturado de entre 5 y 10 miembros donde dicho sistema de anillo puede comprender por lo menos un heteroátomo en el anillo que se selecciona entre N, O y S, donde el sistema de anillo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, ciano, oxo, nitro, hidroxilo, carboxilo, - C(O)H, -NR8R9, -C(O)NR10R11, -NHC(O)R12, -NHSO2R13, -SO2NR14R15, -NHC(O)NR16R17, un grupo que se selecciona entre alquilo C1-6, alquenilo C2-6, alquenilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, haloalquilo C1-6, alquilcarbonilo C1- 6, fenilcarbonilo, cicloalquilo C3-6, fenilo y un anillo heterocíclico saturado o insaturado de 5 o 6 miembros que comprende por lo menos un heteroátomo en el anillo que se selecciona entre N, O y S, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxilo, carboxilo, alquilo C1-6, cicloalquilo C3-6, alcoxi C1-6 y alcoxicarbonilo C1-6, R6 y R7 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 y alquilcarbonilo C1-6, cada uno de los cuales puede estar sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, carbamoilo o alcoxicarbonilo C1-6, o R6 y R7 junto con el átomo de N al cual están unidos forman un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, carbamoilo o alcoxicarbonilo C1-6; R8, R9, R10, R11 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi o carbamoilo; o R10 y R11, junto con el átomo de N al cual están unidos, forman un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente por lo menos con un sustituyente que se selecciona entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R12 representa H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6 donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R13 representa un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R14, R15, R16 y R17 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; o R14 y R15, o R16 y R17 junto con el átomo de N al cual están unidos forma cada uno independientemente un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente por lo menos con un sustituyente que se selecciona entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; o una sal o solvato de los mismos aceptables para uso farmacéutico.
ARP040104881A 2003-12-22 2004-12-22 Derivados de espiro-dihidrobenzofuranos AR046992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303541A SE0303541D0 (sv) 2003-12-22 2003-12-22 New compounds

Publications (1)

Publication Number Publication Date
AR046992A1 true AR046992A1 (es) 2006-01-04

Family

ID=30768856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104881A AR046992A1 (es) 2003-12-22 2004-12-22 Derivados de espiro-dihidrobenzofuranos

Country Status (17)

Country Link
US (2) US7524856B2 (es)
EP (1) EP1699791A1 (es)
JP (1) JP2007515476A (es)
KR (1) KR20060117343A (es)
CN (1) CN1918160A (es)
AR (1) AR046992A1 (es)
AU (1) AU2004303735B2 (es)
BR (1) BRPI0417036A (es)
CA (1) CA2548494A1 (es)
IL (1) IL175958A0 (es)
MX (1) MXPA06007025A (es)
NO (1) NO20063355L (es)
SE (1) SE0303541D0 (es)
TW (1) TW200604197A (es)
UY (1) UY28694A1 (es)
WO (1) WO2005061499A1 (es)
ZA (1) ZA200605082B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1758580A4 (en) 2004-06-24 2008-01-16 Incyte Corp N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
US20080064884A1 (en) * 2006-05-10 2008-03-13 Astrazeneca Ab Novel Process 1
JP2009544609A (ja) * 2006-07-18 2009-12-17 アストラゼネカ・アクチエボラーグ 置換2−アセチルアミノ−アルコキシフェニルの製造方法
CN101553493B (zh) * 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
US20110124613A1 (en) * 2007-02-23 2011-05-26 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2009011653A1 (en) * 2007-07-17 2009-01-22 Astrazeneca Ab A process for the preparation of intermediates and their us in the synthesis of spiropiperidine compounds
WO2009011655A1 (en) * 2007-07-17 2009-01-22 Astrazeneca Ab Splropiperidine compounds, a process of their preparation, pharmaceutical compositions containing them, and their use in the treatment of airway diseases, inflammatory diseases, copd or asthma
WO2009061881A1 (en) * 2007-11-07 2009-05-14 Glaxo Group Limited Spirodihydrobenzofurans as modulators of chemokine receptors
SG176735A1 (en) * 2009-06-10 2012-01-30 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
CN116710673A (zh) 2021-02-08 2023-09-05 日本精工株式会社 反向输入切断离合器

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4166120A (en) 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4166119A (en) 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4263317A (en) 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
US5366986A (en) 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
DE3930262A1 (de) 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DE59610077D1 (de) 1995-05-18 2003-02-27 Altana Pharma Ag Phenyldihydrobenzofurane
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
EP1003743A4 (en) 1997-01-21 2001-04-11 Merck & Co Inc 3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
EP1061076B1 (en) 1998-02-04 2004-12-08 Banyu Pharmaceutical Co., Ltd. N-acyl cyclic amine derivatives
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DE60005545D1 (de) 1999-10-27 2003-10-30 Millennium Pharm Inc Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
AU2001243394A1 (en) * 2000-03-02 2001-09-12 Smith Kline Beecham Corporation Compounds and methods
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
WO2002102387A1 (en) * 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
JP2006511500A (ja) 2002-10-30 2006-04-06 メルク エンド カムパニー インコーポレーテッド γ−アミノアミド系のケモカイン受容体活性調節剤
EA010027B1 (ru) 2002-11-27 2008-06-30 Инсайт Корпорейшн Производные 3-аминопирролидина в качестве модуляторов рецепторов хемокинов
US20070021498A1 (en) 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302755D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP2007530656A (ja) 2004-03-29 2007-11-01 ファイザー株式会社 ORL1受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途

Also Published As

Publication number Publication date
US20090298861A1 (en) 2009-12-03
BRPI0417036A (pt) 2007-02-06
SE0303541D0 (sv) 2003-12-22
AU2004303735A1 (en) 2005-07-07
MXPA06007025A (es) 2006-08-31
AU2004303735B2 (en) 2007-09-20
WO2005061499A1 (en) 2005-07-07
UY28694A1 (es) 2005-07-29
EP1699791A1 (en) 2006-09-13
KR20060117343A (ko) 2006-11-16
CN1918160A (zh) 2007-02-21
NO20063355L (no) 2006-09-22
IL175958A0 (en) 2006-10-05
US7524856B2 (en) 2009-04-28
TW200604197A (en) 2006-02-01
US20070099945A1 (en) 2007-05-03
JP2007515476A (ja) 2007-06-14
ZA200605082B (en) 2007-11-28
CA2548494A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
AR046992A1 (es) Derivados de espiro-dihidrobenzofuranos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR127309A2 (es) Derivados de piridazinona
AR047966A1 (es) Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR069765A1 (es) 4-(4-ciano) 2- tioaril) dihidropirimidonas y su uso
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
AR050617A1 (es) Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR051293A1 (es) Inhibidores bace
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR053992A1 (es) Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
AR060287A1 (es) Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)

Legal Events

Date Code Title Description
FB Suspension of granting procedure